Latest Agenus Inc (AGEN) Headlines
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Investors look to Lighten Up on Shares of Antigenics, Shares Down 10.0% (AGEN)
Comtex SmarTrend(R) - Fri Mar 07, 12:46PM CST
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 10.0% to $4.30 on 1.0x average daily volume. Thus far today, Antigenics has traded 1.2 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-10.0% to the Dow's -0.0%) and underperformed the S&P 500 (-10.0% to the S&P's -0.2%) during today's trading.
Antigenics Has Returned 53.4% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:40AM CST
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on January 21st, 2014 at $3.29. In approximately 1 month, Antigenics has returned 53.42% as of today's recent price of $5.04.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Agenus Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 6:00AM CST
Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Agenus to Advance Three Checkpoint Modulator Antibodies into Development
Business Wire - Wed Mar 05, 6:00AM CST
--Selections made in strategic collaboration with Ludwig Cancer Research
Antigenics Down 8.0%, Shares Slide into the Red (AGEN)
Comtex SmarTrend(R) - Mon Mar 03, 12:46PM CST
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 8.0% to $4.50 on 1.1x average daily volume. Thus far today, Antigenics has traded 1.2 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.9%) during today's trading.
Agenus to Report Fourth Quarter and Year End 2013 Financial Results on March 5, 2014; Conference Call to Follow
Business Wire - Thu Feb 27, 3:00PM CST
Agenus Inc. (NASDAQ: AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014.
54.6% Return Seen to Date on SmarTrend Antigenics Call (AGEN)
Comtex SmarTrend(R) - Thu Feb 27, 9:09AM CST
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on January 21st, 2014 at $3.29. In approximately 1 month, Antigenics has returned 54.64% as of today's recent price of $5.08.
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Traders Get Bullish on Shares of Antigenics, Shares Up 6.4% (AGEN)
Comtex SmarTrend(R) - Mon Feb 24, 10:11AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 6.4% to $4.13 on 1.9x average daily volume. Thus far today, Antigenics has traded 1.5 million shares, vs. average volume of 781,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.9%) and outperformed the S&P 500 (6.4% to the S&P's 0.9%) during today's trading.
Agenus (AGEN) in Focus: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:39AM CST
Agenus Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Major Developments and Milestones Established This Week for PetroTech, Tanke, Strategic Global, Raptor and Agenus
PR Newswire - Thu Feb 20, 12:58PM CST
Market snapshot updates and news developments for advancing cannabis and healthcare stocks: PetroTech Oil and Gas Inc. (OTC: PTOG), Tanke, Incorporated (OTC: TNKE), Strategic Global Investments, Inc. (OTC: STBV), Raptor Pharmaceutical Corp. (NASDAQ: RPTP) and Agenus Inc. (NASDAQ: AGEN).
Antigenics Up 6.8%, Shares Break Through Resistance (AGEN)
Comtex SmarTrend(R) - Thu Feb 20, 10:12AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 6.8% to $3.60 on 1.9x average daily volume. Antigenics has traded 1.3 million shares thus far today, vs. average volume of 663,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.4%) and outperformed the S&P 500 (6.8% to the S&P's 0.3%) during today's trading.
Agenus Inc. (AGEN) Catches Eye: Stock Surges 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:44AM CST
Agenus Inc. was a big mover last session, as the company saw its shares surge nearly 11% on the day.
Agenus Completes Acquisition of 4-Antibody
Business Wire - Thu Feb 13, 6:00AM CST
Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.
Hot Stock: Antigenics, Shares Gain 5.8% (AGEN)
Comtex SmarTrend(R) - Tue Feb 11, 11:42AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 5.8% to $3.09 on 1.2x average daily volume. Antigenics has traded 705,000 shares thus far today, vs. average volume of 575,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's 0.9%) and outperformed the S&P 500 (5.8% to the S&P's 0.8%) during today's trading.
Agenus Announces Closing of Public Offering and Exercise of Over-Allotment Option
Business Wire - Mon Feb 10, 9:01AM CST
Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced underwritten registered public offering of common stock. The total number of shares of common stock sold was 22,236,000, composed of 19,335,653 shares of common stock initially offered and an additional 2,900,347 shares of common stock sold pursuant to the exercise of the underwriters' over-allotment option, in each case at a public offering price of $2.70 per share. All of the shares in the offering were sold by Agenus. The net proceeds to Agenus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $56.0 million.
Agenus to Present at BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:00AM CST
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that the company will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th at 9:30 am EST in the Conrad Room. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Investors look to Lighten Up on Shares of Antigenics, Shares Down 10.0% (AGEN)
Comtex SmarTrend(R) - Fri Mar 07, 12:46PM CST
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 10.0% to $4.30 on 1.0x average daily volume. Thus far today, Antigenics has traded 1.2 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-10.0% to the Dow's -0.0%) and underperformed the S&P 500 (-10.0% to the S&P's -0.2%) during today's trading.
Antigenics Has Returned 53.4% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:40AM CST
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on January 21st, 2014 at $3.29. In approximately 1 month, Antigenics has returned 53.42% as of today's recent price of $5.04.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Agenus Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 6:00AM CST
Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Agenus to Advance Three Checkpoint Modulator Antibodies into Development
Business Wire - Wed Mar 05, 6:00AM CST
--Selections made in strategic collaboration with Ludwig Cancer Research
Antigenics Down 8.0%, Shares Slide into the Red (AGEN)
Comtex SmarTrend(R) - Mon Mar 03, 12:46PM CST
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 8.0% to $4.50 on 1.1x average daily volume. Thus far today, Antigenics has traded 1.2 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.9%) during today's trading.
Agenus to Report Fourth Quarter and Year End 2013 Financial Results on March 5, 2014; Conference Call to Follow
Business Wire - Thu Feb 27, 3:00PM CST
Agenus Inc. (NASDAQ: AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014.
54.6% Return Seen to Date on SmarTrend Antigenics Call (AGEN)
Comtex SmarTrend(R) - Thu Feb 27, 9:09AM CST
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on January 21st, 2014 at $3.29. In approximately 1 month, Antigenics has returned 54.64% as of today's recent price of $5.08.
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Traders Get Bullish on Shares of Antigenics, Shares Up 6.4% (AGEN)
Comtex SmarTrend(R) - Mon Feb 24, 10:11AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 6.4% to $4.13 on 1.9x average daily volume. Thus far today, Antigenics has traded 1.5 million shares, vs. average volume of 781,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.9%) and outperformed the S&P 500 (6.4% to the S&P's 0.9%) during today's trading.
Agenus (AGEN) in Focus: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:39AM CST
Agenus Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Major Developments and Milestones Established This Week for PetroTech, Tanke, Strategic Global, Raptor and Agenus
PR Newswire - Thu Feb 20, 12:58PM CST
Market snapshot updates and news developments for advancing cannabis and healthcare stocks: PetroTech Oil and Gas Inc. (OTC: PTOG), Tanke, Incorporated (OTC: TNKE), Strategic Global Investments, Inc. (OTC: STBV), Raptor Pharmaceutical Corp. (NASDAQ: RPTP) and Agenus Inc. (NASDAQ: AGEN).
Antigenics Up 6.8%, Shares Break Through Resistance (AGEN)
Comtex SmarTrend(R) - Thu Feb 20, 10:12AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 6.8% to $3.60 on 1.9x average daily volume. Antigenics has traded 1.3 million shares thus far today, vs. average volume of 663,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.4%) and outperformed the S&P 500 (6.8% to the S&P's 0.3%) during today's trading.
Agenus Inc. (AGEN) Catches Eye: Stock Surges 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:44AM CST
Agenus Inc. was a big mover last session, as the company saw its shares surge nearly 11% on the day.
Agenus Completes Acquisition of 4-Antibody
Business Wire - Thu Feb 13, 6:00AM CST
Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.
Hot Stock: Antigenics, Shares Gain 5.8% (AGEN)
Comtex SmarTrend(R) - Tue Feb 11, 11:42AM CST
Antigenics (NASDAQ:AGEN) is one of today's best performing low-priced stocks, up 5.8% to $3.09 on 1.2x average daily volume. Antigenics has traded 705,000 shares thus far today, vs. average volume of 575,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's 0.9%) and outperformed the S&P 500 (5.8% to the S&P's 0.8%) during today's trading.
Agenus Announces Closing of Public Offering and Exercise of Over-Allotment Option
Business Wire - Mon Feb 10, 9:01AM CST
Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced underwritten registered public offering of common stock. The total number of shares of common stock sold was 22,236,000, composed of 19,335,653 shares of common stock initially offered and an additional 2,900,347 shares of common stock sold pursuant to the exercise of the underwriters' over-allotment option, in each case at a public offering price of $2.70 per share. All of the shares in the offering were sold by Agenus. The net proceeds to Agenus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $56.0 million.
Agenus to Present at BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:00AM CST
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that the company will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th at 9:30 am EST in the Conrad Room. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
